DGAP-News: MorphoSys AG / Key word(s): AGM/EGM
10.04.2019 / 22:01
The issuer is solely responsible for the content of this announcement.
Planegg/Munich, Germany, April 10, 2019
MorphoSys Nominates New Candidate for Supervisory Board
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company’s ordinary Annual General Meeting (AGM), which will take place on Wednesday, May 22, 2019.
MorphoSys’s Supervisory Board has nominated Sharon Curran as candidate to be elected as new additional Supervisory Board member at the Company’s AGM. Furthermore, the Supervisory Board will propose the re-election of Krisja Vermeylen, whose term of office would expire with the conclusion of the AGM 2019.
“We are delighted to present Ms Curran for election to the MorphoSys Supervisory Board. She brings significant experience in product management, marketing and commercialization of pharmaceuticals, particularly in the United States and Ireland,” said Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys AG.
Ms Curran currently serves as a Non-Executive Director in the life sciences and healthcare industries. Prior to that, Ms Curran worked for AbbVie Inc, Illinois, USA as Vice President, Global Specialty Franchise and Customer Excellence and has also held a number of other senior positions in her career including Vice President Global Marketing Specialty, AbbVie; Global Brand and Area Commercial Director, Abbott MBO and Division Head, Eli Lilly UK & Ireland. Ms Curran brings extensive commercial and specialty pharmaceutical experience to the Company. She holds an Executive Master of Science, Business Administration from Trinity College Dublin, Ireland and a Bachelor of Science in Biotechnology from Dublin City University, Ireland.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
MorphoSys forward looking statements
For more information, please contact:
Dr. Julia Neugebauer
Dr. Verena Kupas
Tel: +49 (0) 89 / 899 27-404
10.04.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)89 899 27-0|
|Fax:||+49 (0)89 899 27-222|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq|
|EQS News ID:||798529|
|End of News||DGAP News Service|